Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

S

Spanish Breast Cancer Research Group (GEICAM)

Status and phase

Completed
Phase 4

Conditions

Breast Neoplasms

Treatments

Drug: Pegylated liposomal doxorubicin

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00128778
GEICAM 2001-01

Details and patient eligibility

About

This is a randomized, prospective and multicenter phase IV clinical trial, which has been designed as a phase III study. One hundred fifty-four women (77 per treatment arm) will be recruited in the study.

Full description

The main variable is time to disease progression. All patients must be treated with first line of induction chemotherapy, consisting of doxorubicin 75 mg/m2, day 1 every 3 weeks, and docetaxel, 100 mg/m2, day 1 every 3 weeks. Both drugs must be administered sequentially. Patients previously treated with anthracyclines must receive 2 courses of doxorubicin and 4 courses of docetaxel. Otherwise, patients will receive 3 courses of doxorubicin followed by 3 courses of docetaxel. Patients with complete response, partial response or stable disease are eligible for 2001-01 study. The investigators assume that maintenance treatment with Caelyx will increase mean time to progression from 10, 46 months (observation) to 17, 43 months. Expected difference in mean time to progression is 6, 97 months (Hazard ratio = 0.6). With an alpha error of 0.01 (unilateral) and power of 80%, 77 patients per arm are needed, 154 patients in total.

Enrollment

288 patients

Sex

Female

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Written informed consent.
  • Patients with metastatic breast cancer who have responded to a first line induction chemotherapy treatment.
  • Age: at least 18 years old.
  • Performance status Eastern Cooperative Oncology Group (ECOG) scale 0, 1, 2.
  • Normal cardiac function, confirmed by left ventricular ejection fraction (LVEF).
  • Hematology: leucocytes >= 4 x 10^9/l; neutrophils >= 2.0 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin <= 10 g/dl.
  • Hepatic function: total bilirubin < 1 upper limit of normal (UNL); aspartate aminotransferase (ASAT) (SGOT) and alanine aminotransferase (ALAT) (SGPT) < 2.5 UNL; alkaline phosphatase < 5 UNL. Patients with ASAT (SGOT) and ALAT (SGPT) > 1.5 UNL and alkaline phosphatase > 2.5 UNL are not eligible.
  • Renal function: creatinine < 175 mmol/l (2 mg/dl); creatinine clearance > 45 ml/min.

Exclusion criteria

  • Pregnant or lactating patients.
  • Previous cardiac dysfunction grade II or higher as per New York Heart Association, along with congestive cardiac failure.
  • Hypersensitivity to anthracyclines or Cremophor®.
  • Clinically significant hepatic dysfunction.
  • Current uncontrolled infection.
  • Mental confusion and lack of orientation.
  • Any circumstance precluding an adequate follow-up.
  • Radiotherapy in the previous 4 weeks.
  • Any other concurrent neoplasm, except for basal cell carcinoma or in situ carcinoma.
  • Symptomatic metastasis in the brain.
  • Previous radiotherapy radiating a third of haematopoietic centres.
  • Males.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

288 participants in 2 patient groups

Arm A: PLD
Experimental group
Description:
Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
Treatment:
Drug: Pegylated liposomal doxorubicin
Arm B: Observation
No Intervention group
Description:
Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems